Cargando…

Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis

Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Tomoko, Uozumi, Ryuji, Kawazoe, Hitoshi, Kitazume, Yoshiko, Iihara, Hirotoshi, Fujii, Hironori, Takahashi, Masaya, Arai, Takahiro, Murachi, Yasushi, Sato, Yumiko, Mikami, Takahiro, Hashiguchi, Koji, Yoshizawa, Tomoe, Takahashi, Katsuyuki, Fujita, Yukiyoshi, Hosokawa, Yuki, Morozumi, Issei, Tsuchiya, Masami, Yokoyama, Atsushi, Hashimoto, Hironobu, Furukawa, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414027/
https://www.ncbi.nlm.nih.gov/pubmed/36046656
http://dx.doi.org/10.7150/jca.73385
_version_ 1784775894283321344
author Yamazaki, Tomoko
Uozumi, Ryuji
Kawazoe, Hitoshi
Kitazume, Yoshiko
Iihara, Hirotoshi
Fujii, Hironori
Takahashi, Masaya
Arai, Takahiro
Murachi, Yasushi
Sato, Yumiko
Mikami, Takahiro
Hashiguchi, Koji
Yoshizawa, Tomoe
Takahashi, Katsuyuki
Fujita, Yukiyoshi
Hosokawa, Yuki
Morozumi, Issei
Tsuchiya, Masami
Yokoyama, Atsushi
Hashimoto, Hironobu
Furukawa, Tetsuya
author_facet Yamazaki, Tomoko
Uozumi, Ryuji
Kawazoe, Hitoshi
Kitazume, Yoshiko
Iihara, Hirotoshi
Fujii, Hironori
Takahashi, Masaya
Arai, Takahiro
Murachi, Yasushi
Sato, Yumiko
Mikami, Takahiro
Hashiguchi, Koji
Yoshizawa, Tomoe
Takahashi, Katsuyuki
Fujita, Yukiyoshi
Hosokawa, Yuki
Morozumi, Issei
Tsuchiya, Masami
Yokoyama, Atsushi
Hashimoto, Hironobu
Furukawa, Tetsuya
author_sort Yamazaki, Tomoko
collection PubMed
description Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)RAs) in early-stage colorectal cancer (CRC) patients using real-world data. Methods: This multicenter, retrospective, observational study included consecutive patients with stage II-III CRC who received either capecitabine monotherapy or the CapeOX regimen (capecitabine and oxaliplatin) as adjuvant therapy between January 2009 and December 2014 in Japan. Relapse-free survival (RFS) and overall survival were estimated using the Kaplan-Meier method. Additionally, multivariable Cox proportional hazards model, propensity score adjustment, and inverse probability of treatment weighting analyses were performed. Results: In total, 552 patients were included in this study, of which 30 were co-administered H(2)RAs. RFS at five years was 76.7% (95% confidence interval [CI]: 57.2-88.1%) and 79.8% (95% CI: 76.0-83.0%) in the H(2)RA and non-H(2)RA groups, respectively. Multivariable Cox proportional hazards model and propensity score-adjusted analyses showed that the co-administration of H(2)RAs was associated with a poor RFS among those receiving capecitabine monotherapy (hazard ratio [HR], 2.01; 95% CI: 0.86-4.70 and HR, 1.81; 95% CI: 0.77-4.22, respectively). In contrast, these results were inconsistent with the group receiving the CapeOX regimen. Conclusions: The study findings suggest that the co-administration of H(2)RAs may not reduce the effectiveness of capecitabine therapy in patients with early-stage CRC. To confirm this relationship, a prospective study with a pharmacokinetic approach is needed.
format Online
Article
Text
id pubmed-9414027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-94140272022-08-30 Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis Yamazaki, Tomoko Uozumi, Ryuji Kawazoe, Hitoshi Kitazume, Yoshiko Iihara, Hirotoshi Fujii, Hironori Takahashi, Masaya Arai, Takahiro Murachi, Yasushi Sato, Yumiko Mikami, Takahiro Hashiguchi, Koji Yoshizawa, Tomoe Takahashi, Katsuyuki Fujita, Yukiyoshi Hosokawa, Yuki Morozumi, Issei Tsuchiya, Masami Yokoyama, Atsushi Hashimoto, Hironobu Furukawa, Tetsuya J Cancer Research Paper Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)RAs) in early-stage colorectal cancer (CRC) patients using real-world data. Methods: This multicenter, retrospective, observational study included consecutive patients with stage II-III CRC who received either capecitabine monotherapy or the CapeOX regimen (capecitabine and oxaliplatin) as adjuvant therapy between January 2009 and December 2014 in Japan. Relapse-free survival (RFS) and overall survival were estimated using the Kaplan-Meier method. Additionally, multivariable Cox proportional hazards model, propensity score adjustment, and inverse probability of treatment weighting analyses were performed. Results: In total, 552 patients were included in this study, of which 30 were co-administered H(2)RAs. RFS at five years was 76.7% (95% confidence interval [CI]: 57.2-88.1%) and 79.8% (95% CI: 76.0-83.0%) in the H(2)RA and non-H(2)RA groups, respectively. Multivariable Cox proportional hazards model and propensity score-adjusted analyses showed that the co-administration of H(2)RAs was associated with a poor RFS among those receiving capecitabine monotherapy (hazard ratio [HR], 2.01; 95% CI: 0.86-4.70 and HR, 1.81; 95% CI: 0.77-4.22, respectively). In contrast, these results were inconsistent with the group receiving the CapeOX regimen. Conclusions: The study findings suggest that the co-administration of H(2)RAs may not reduce the effectiveness of capecitabine therapy in patients with early-stage CRC. To confirm this relationship, a prospective study with a pharmacokinetic approach is needed. Ivyspring International Publisher 2022-08-08 /pmc/articles/PMC9414027/ /pubmed/36046656 http://dx.doi.org/10.7150/jca.73385 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Yamazaki, Tomoko
Uozumi, Ryuji
Kawazoe, Hitoshi
Kitazume, Yoshiko
Iihara, Hirotoshi
Fujii, Hironori
Takahashi, Masaya
Arai, Takahiro
Murachi, Yasushi
Sato, Yumiko
Mikami, Takahiro
Hashiguchi, Koji
Yoshizawa, Tomoe
Takahashi, Katsuyuki
Fujita, Yukiyoshi
Hosokawa, Yuki
Morozumi, Issei
Tsuchiya, Masami
Yokoyama, Atsushi
Hashimoto, Hironobu
Furukawa, Tetsuya
Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title_full Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title_fullStr Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title_full_unstemmed Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title_short Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
title_sort association between the co-administration of histamine h(2) receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: propensity score analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414027/
https://www.ncbi.nlm.nih.gov/pubmed/36046656
http://dx.doi.org/10.7150/jca.73385
work_keys_str_mv AT yamazakitomoko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT uozumiryuji associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT kawazoehitoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT kitazumeyoshiko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT iiharahirotoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT fujiihironori associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT takahashimasaya associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT araitakahiro associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT murachiyasushi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT satoyumiko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT mikamitakahiro associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT hashiguchikoji associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT yoshizawatomoe associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT takahashikatsuyuki associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT fujitayukiyoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT hosokawayuki associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT morozumiissei associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT tsuchiyamasami associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT yokoyamaatsushi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT hashimotohironobu associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis
AT furukawatetsuya associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis